DRC Gets 70,000 Ebola Vaccines to Fight New Outbreak

Health workers in the Democratic Republic of Congo now have access to 70,000 Ebola vaccine doses, offering hope in the fight against a spreading outbreak that has challenged scientists with its unusual virus strain.

The World Health Organization and Africa Centres for Disease Control delivered the vaccines after the DRC government requested help from the global emergency stockpile last week. The Ervebo vaccine has proven effective against the most common Ebola strain, but this outbreak involves a different type called Bundibugyo virus.

That difference matters. Scientists don't yet know if Ervebo can protect people against Bundibugyo, though early lab and animal studies suggest it might help.

Out of the 70,000 doses, 50,000 will go directly to frontline and health workers who face the highest risk of infection. The remaining 20,000 will support a Phase III clinical trial to determine whether the vaccine actually works against this virus strain.

The outbreak has grown rapidly since officials declared it on May 15. As of August 12, authorities had confirmed 4,665 cases and 2,184 deaths across 54 health zones in six provinces.

Population movement, mining activities, and cross-border travel with Uganda and South Sudan have accelerated the spread. WHO describes this as the largest Ebola outbreak ever reported in the DRC, with transmission currently in an intense phase.

The dual approach of protecting health workers while gathering scientific evidence could strengthen responses to future outbreaks. Everyone receiving the vaccine will learn about its potential benefits and limitations before giving informed consent.

The Ripple Effect

Meanwhile, scientists at the University of Oxford launched the first clinical trial of a vaccine specifically designed for Bundibugyo virus in July. The experimental ChAdOx1 BDBV vaccine, developed with the Serum Institute of India and the Coalition for Epidemic Preparedness Innovations, targets this exact virus strain.

The current response combines immediate protection with long-term solutions. WHO and Africa CDC emphasized that success depends on community involvement, ensuring that affected populations understand the vaccines and play a central role in stopping transmission.

The global partnership funding these efforts includes WHO, the International Federation of Red Cross and Red Crescent Societies, Doctors Without Borders, UNICEF, and Gavi, the Vaccine Alliance. Their collaboration demonstrates how coordinated international response can deliver resources where they're needed most.

Health authorities are working to protect vulnerable communities while building knowledge that could save lives in future outbreaks across Africa and beyond.